Marechale Capital PLC (GB:MAC)
LSE:MAC
Top Page
Marechale Capital
(LSE:MAC)
Select Model
Select Model
Rating:50Neutral
Price Target:
2.00 p
▲(21.21% Upside)
Action:ReiteratedDate:01/08/26
The score is primarily held back by weak financial performance (negative margins and persistently negative operating/free cash flow), with only moderate support from technical strength (price above key moving averages but overbought RSI). Valuation is also constrained by a negative P/E reflecting losses.
Positive Factors
Balance Sheet Strength
A low debt-to-equity ratio and stable equity position provide durable financial flexibility. Over a 2–6 month horizon this reduces refinancing risk, supports working capital during cyclical revenue weakness, and preserves options for strategic investments or restructurings.
Negative Factors
Negative Profitability
Persistently negative EBIT and net margins erode retained capital and limit the company’s ability to self-finance. Over a multi-month horizon this undermines returns on equity, reduces reinvestment capacity, and increases the likelihood management must pursue costly external funding to sustain operations.
Read all positive and negative factors
Positive Factors
Negative Factors
Balance Sheet Strength
A low debt-to-equity ratio and stable equity position provide durable financial flexibility. Over a 2–6 month horizon this reduces refinancing risk, supports working capital during cyclical revenue weakness, and preserves options for strategic investments or restructurings.
Read all positive factors
Marechale Capital (MAC) vs. iShares MSCI United Kingdom ETF (EWC)
Market Cap
£2.03M
Dividend YieldN/A
Average Volume (3M)337.03K
Price to Earnings (P/E)―
Beta (1Y)1.69
Revenue Growth-57.15%
EPS Growth-77.78%
CountryUK
Employees4
SectorFinancial
Sector Strength70
IndustryFinancial - Capital Markets
Share Statistics
EPS (TTM)N/A
Shares Outstanding119,441,250
10 Day Avg. Volume145,650
30 Day Avg. Volume337,027
Financial Highlights & Ratios
PEG Ratio-0.05
Price to Book (P/B)0.43
Price to Sales (P/S)3.22
P/FCF Ratio-7.10
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Marechale Capital Business Overview & Revenue Model
Company Description
Marechale Capital (MAC) is a leading investment and financial advisory firm based in the UK, specializing in providing tailored capital solutions and strategic advice to companies across various sectors including technology, healthcare, and renewa...
How the Company Makes Money
null...
Marechale Capital Financial Statement Overview
Summary
Income Statement
45
Neutral
Balance Sheet
60
Neutral
Cash Flow
40
Negative
| Breakdown | TTM | Apr 2024 | Apr 2023 | Apr 2022 | Apr 2021 | Apr 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 373.10K | 409.41K | 668.82K | 375.73K | 621.57K | 398.45K |
| Gross Profit | 316.48K | 409.41K | 197.38K | 97.07K | 329.94K | 253.95K |
| EBITDA | -336.76K | -338.30K | -182.56K | -52.12K | 2.72M | 202.59K |
| Net Income | -335.58K | -337.32K | -182.99K | -425.52K | 2.56M | 245.89K |
Balance Sheet | ||||||
| Total Assets | 3.19M | 3.18M | 3.43M | 3.35M | 3.73M | 796.97K |
| Cash, Cash Equivalents and Short-Term Investments | 3.04M | 3.02M | 3.29M | 3.15M | 3.54M | 656.36K |
| Total Debt | 7.50K | 2.50K | 22.50K | 32.50K | 42.50K | 50.00K |
| Total Liabilities | 123.20K | 145.99K | 84.53K | 124.06K | 99.87K | 111.21K |
| Stockholders Equity | 3.06M | 3.04M | 3.35M | 3.23M | 3.63M | 685.75K |
Cash Flow | ||||||
| Free Cash Flow | -57.79K | -185.71K | -256.06K | -367.22K | -131.85K | -92.51K |
| Operating Cash Flow | -238.85K | -185.71K | -256.06K | -367.22K | -131.85K | -191.79K |
| Investing Cash Flow | 50.00K | 160.08K | -3.64K | 226.93K | -42.46K | -49.65K |
| Financing Cash Flow | 192.50K | -10.41K | 225.10K | -8.42K | 355.00K | 317.49K |
Marechale Capital Technical Analysis
Negative
1.65
Price Trends
2.10
Negative
2.00
Negative
1.91
Negative
Market Momentum
-0.11
Positive
21.87
Positive
33.33
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GB:MAC, the sentiment is Negative. The current price of 1.65 is below the 20-day moving average (MA) of 1.87, below the 50-day MA of 2.10, and below the 200-day MA of 1.91, indicating a bearish trend. The MACD of -0.11 indicates Positive momentum. The RSI at 21.87 is Positive, neither overbought nor oversold. The STOCH value of 33.33 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for GB:MAC.
Marechale Capital Peers Comparison
UnderperformOutperform
Sector (68)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
68 Neutral | $18.00B | 11.42 | 9.92% | 3.81% | 9.73% | 1.22% | |
61 Neutral | £3.20M | 0.25 | 66.17% | 26.13% | ― | ― | |
60 Neutral | £34.06M | 13.98 | 3.68% | 7.96% | -9.55% | ― | |
58 Neutral | £121.91M | 3.75 | 4.98% | ― | 15.42% | ― | |
56 Neutral | £14.77M | -2.99 | 14.74% | 2.12% | -17.37% | ― | |
50 Neutral | £2.03M | -2.62 | -10.57% | ― | -57.15% | -77.78% |
* Financial Sector Average
GB:MAC
Marechale Capital
1.70
0.40
30.77%
GB:JIM
Jarvis Securities
7.15
-29.28
-80.37%
GB:TAVI
Tavistock Investments
3.35
-0.31
-8.47%
GB:CAV
finnCap Group plc
9.10
1.51
19.89%
GB:PEEL
Peel Hunt Limited
104.50
29.00
38.41%
Marechale Capital Corporate Events
Business Operations and StrategyFinancial DisclosuresPrivate Placements and Financing
Marechale Capital Posts Wider Interim Loss but Touts Stronger Pipeline and Strategic Investors
Negative
Jan 19, 2026
Marechale Capital reported a weaker first half for the six months to 31 October 2025, with revenue falling to £111,932 and gross profit halving to £55,310, resulting in an operating loss of £177,066 and a loss before tax of £17...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.